Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
Brief Summary: CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of secukinumab in both the fixed interval regimen and the retreatment at start of relapse regimen. All subjects who completed the full study treatment period (52 weeks) in the cores studies CAIN457A2304 and CAIN457A2307 were eligible to participate in this extension study. In this extension study, the prefilled syringe (PFS) liquid formulation of secukinumab was used.


Options:
A: Arm Label: 80 mg ixekizumab Dosing Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 80 mg ixekizumab Dosing Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: 80 mg ixekizumab Dosing Regimen | Arm Label: 50 mg etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: 50 mg etanercept | Arm Label: Placebo for ixekizumab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg ixekizumab Dosing Regimen; Assigned to Arm(s): 80 mg ixekizumab Dosing Regimen 1, 80 mg ixekizumab Dosing Regimen 2, 80 mg ixekizumab Dosing Regimen 3 | Intervention Type: DRUG; Name: 50 mg etanercept; Assigned to Arm(s): 50 mg etanercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo for ixekizumab
B: Arm Label: Adalimumab (Humira); Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab (Humira) | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Injection | Arm Label: NB-UVB phototherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: NB-UVB phototherapy | Intervention Type: DRUG; Name: Adalimumab (Humira); Assigned to Arm(s): Adalimumab (Humira) | Intervention Type: DRUG; Name: Placebo Injection; Assigned to Arm(s): Placebo Injection | Intervention Type: OTHER; Name: NB-UVB phototherapy; Assigned to Arm(s): NB-UVB phototherapy
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bimekizumab dosing regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 4; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab, Other: Placebo | Arm Label: Bimekizumab dosing regimen 5; Type: EXPERIMENTAL; Interventions: Drug: Bimekizumab | Intervention Type: DRUG; Name: Bimekizumab; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Bimekizumab dosing regimen 5 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Bimekizumab dosing regimen 1, Bimekizumab dosing regimen 2, Bimekizumab dosing regimen 3, Bimekizumab dosing regimen 4, Placebo
D: Arm Label: AIN457 150 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 150 mg - Start of relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 150 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Fixed Interval (FI); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: AIN457 300 mg - Start of Relapse (SoR); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg, Drug: Placebo | Arm Label: AIN457 300 mg - Open Label (OL); Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Intervention Type: DRUG; Name: AIN457 150 mg; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR) | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg - Fixed Interval (FI), AIN457 300 mg - Open Label (OL), AIN457 300 mg - Start of Relapse (SoR) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150 mg - Fixed Interval (FI), AIN457 150 mg - Start of relapse (SoR), AIN457 300 mg - Start of Relapse (SoR)

Answer: D